Investigating how MITF affects aggressive prostate cancer
Determine the Microphthalmia Transcription Factor (MITF)-regulated cell rewiring mechanisms in lethal prostate cancer
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-10876230
This study is looking into why some advanced prostate cancers are tough to treat and how a specific factor in the cancer cells might be making them more aggressive, with the hope that this could lead to better treatment options for patients facing serious prostate cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10876230 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the biological mechanisms that make prostate cancer aggressive and resistant to treatment, particularly in its advanced stages. By analyzing human prostate cancer models and public databases, the study aims to identify how the Microphthalmia Transcription Factor (MITF) influences cancer cell behavior and treatment resistance. Patients may benefit from insights that could lead to new therapeutic strategies targeting these mechanisms, ultimately improving outcomes for those with lethal prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced castration-resistant prostate cancer.
Not a fit: Patients with early-stage prostate cancer or those who do not have castration-resistant disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that specifically target the aggressive nature of lethal prostate cancer.
How similar studies have performed: Previous research has shown promising results in understanding cancer biology through similar molecular approaches, indicating potential for success in this area.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOMINGO-DOMENECH, JOSEP MARIA — MAYO CLINIC ROCHESTER
- Study coordinator: DOMINGO-DOMENECH, JOSEP MARIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Genes, Cancer Patient